Quralis, a US-based precision therapeutics developer founded by Harvard University professors, has launched with an undisclosed amount of seed funding from investors including Amgen Ventures, a division of biopharmaceutical developer Amgen.
The round included Alexandria Venture Investments, the corporate venturing arm of life science real estate developer Alexandria Real Estate Equities, and MP Healthcare Venture Management, part of Mitsubishi Tanabe Pharma Corporation, owned in turn by conglomerate Mitsubishi Chemical.
Quralis hopes to exploit genetic research to develop therapeutics for amyotrophic…
